DSIpharma
Wilmington, US · Founded 2025 · Delaware corporation
Find your way into DSIpharma
Sign up to see every warm intro you have to DSIpharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the DSIpharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
KA
Kysha Ayana Pierre-LouisNamed on SEC filing
MR
Mark RidallNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$951.3K disclosed across 1 round · 2025
▶$951.3KraisedOct 2026 · 18 investors · Other Health CareRule 506(b)
▶$951.3KraisedOct 2026 · 18 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mark RidallExecutive Officer, Director
- Kysha Ayana Pierre-LouisExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $951.3K
- Proceeds to insiders
- $90K
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has DSIpharma raised?
- DSIpharma has disclosed $951.3K raised across 1 round.
- Where is DSIpharma headquartered?
- DSIpharma is headquartered in Wilmington, US.